| 1 |
34335273 | Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. | 2021 |
3 |
| 2 |
34442334 | Functional Characterization of 21 Rare Allelic CYP1A2 Variants Identified in a Population of 4773 Japanese Individuals by Assessing Phenacetin O-Deethylation. | 2021 Jul 22 |
2 |
| 3 |
34528455 | The pharmacogenetics of treatment with olanzapine. | 2021 Sep |
1 |
| 4 |
32070304 | The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine. | 2020 Feb 18 |
1 |
| 5 |
32250470 | The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. | 2020 Oct |
1 |
| 6 |
32992097 | Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients. | 2020 Nov |
1 |
| 7 |
30888624 | A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects. | 2019 May |
1 |
| 8 |
26856397 | Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. | 2016 Mar |
3 |
| 9 |
25090458 | CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. | 2015 Apr |
4 |
| 10 |
24929949 | Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers. | 2014 Aug |
1 |
| 11 |
23492908 | Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure. | 2013 May |
5 |
| 12 |
23641727 | Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. | 2013 Sep |
3 |
| 13 |
23930678 | Pharmacogenetics of olanzapine metabolism. | 2013 Aug |
2 |
| 14 |
22554278 | Measurement of CYP1A2 activity: a focus on caffeine as a probe. | 2012 Jun 1 |
1 |
| 15 |
21395655 | The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. | 2011 Apr |
1 |
| 16 |
19636338 | Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. | 2010 Feb |
4 |
| 17 |
20143052 | Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. | 2010 May |
1 |
| 18 |
19490292 | A review of smoking cessation: potentially risky effects on prescribed medications. | 2009 Jun |
1 |
| 19 |
19794359 | Smoking and schizophrenia. | 2009 Sep |
1 |
| 20 |
18537577 | Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. | 2008 Jun |
1 |
| 21 |
16969362 | Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. | 2007 Oct |
1 |
| 22 |
17214606 | Metabolic drug interactions with newer antipsychotics: a comparative review. | 2007 Jan |
1 |
| 23 |
17823102 | Drug interactions with smoking. | 2007 Sep 15 |
1 |
| 24 |
16805946 | Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. | 2006 Jul |
2 |
| 25 |
17089108 | The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. | 2006 Dec |
2 |
| 26 |
15738749 | Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. | 2005 Apr |
3 |
| 27 |
15883149 | The dosing of atypical antipsychotics. | 2005 May-Jun |
2 |
| 28 |
15323601 | Variables associated with high olanzapine dosing in a state hospital. | 2004 Aug |
2 |
| 29 |
15545309 | Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. | 2004 Dec |
4 |
| 30 |
26984311 | Olanzapine metabolism by CYP1A2/CYP2D6 and hyperglycaemia. | 2004 Aug |
2 |
| 31 |
12640212 | Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. | 2003 Apr |
5 |
| 32 |
12644842 | Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. | 2003 May |
3 |
| 33 |
12665390 | Fatalities associated with therapeutic use and overdose of atypical antipsychotics. | 2003 |
2 |
| 34 |
12670127 | Interactions between the cytochrome P450 system and the second-generation antipsychotics. | 2003 Mar |
1 |
| 35 |
11981356 | Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. | 2002 May |
2 |
| 36 |
12172335 | Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. | 2002 Aug |
1 |
| 37 |
12186270 | New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. | 2002 Jul |
1 |
| 38 |
12352274 | Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. | 2002 Oct |
1 |
| 39 |
11477325 | Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. | 2001 Aug |
1 |
| 40 |
11699614 | Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. | 2001 Sep |
1 |
| 41 |
10422890 | Drug metabolism and atypical antipsychotics. | 1999 Jun |
1 |
| 42 |
10511917 | Olanzapine. Pharmacokinetic and pharmacodynamic profile. | 1999 Sep |
1 |
| 43 |
9855322 | Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. | 1998 Nov-Dec |
1 |
| 44 |
9860152 | A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. | 1998 Oct |
4 |